Abstract
Introduction
We have previously presented early results of untreated CHL patients treated with concurrent pembrolizumab + AVD (Lynch et al. ASH 2021) which was highly effective but had increased rates of false positive PET/CT results leading to additional scans and/or biopsies. Circulating tumor DNA (ctDNA) may represent a more sensitive and specific method of response assessment. Herein we report updated clinical results with correlation of dynamic ctDNA monitoring as well as data on total metabolic tumor volume (TMTV).
Methods
This was a single arm pilot study combining pembrolizumab with AVD in untreated CHL of any stage. Pembrolizumab 200 mg IV was administered every 21 days concurrently with AVD chemotherapy. AVD was administered at the standard dosing and schedule. Plasma samples were analyzed for ctDNA at baseline, post cycle 1 (if available), post cycle 2, and end of treatment. ctDNA levels were quantified as haploid genome equivalents/mL plasma using CAPP-Seq and PhasED-Seq (Kurtz et al. Nat Biotech 2021). Baseline, post cycle 2, and end of treatment PET/CT were analyzed for TMTV using a threshold based semiautomated technique that included any tumor with standardized uptake value (SUV) above the liver background SUVmax using MIM Encore (version 7.1.3 Cleveland, OH).
Results
Among the 30 patients enrolled, 29 are evaluable for response and/or exploratory analysis (one patient withdrew from study treatment prior to any response assessment). With median follow-up of 21 months, 2-year PFS and OS were 97% and 100%, respectively. While 5 patients had residual FDG uptake at EOT, only 1 (20%) has developed recurrent Hodgkin lymphoma. ctDNA data was available for 18 patients. Pretreatment ctDNA levels were significantly correlated with TMTV (RS=0.68, p=0.003). 17/18 patients had detectable ctDNA at baseline and were therefore evaluable for MRD assessment. Among 8 PET2+ patients, only 1 patient had detectable ctDNA, and ctDNA became undetectable by the end of treatment. Importantly, of these 8 patients, none have relapsed. Only 1/9 (11%) patients who were PET2- had detectable ctDNA after 2 cycles, and the cancer ultimately recurred. At EOT for those who received > 2 cycles, 2/14 had detectable ctDNA (one CHL relapse, one with secondary DLBCL 11 months later). ctDNA analyses for the remaining patients are in process and will be presented at the meeting.
Conclusion
Concurrent pembrolizumab + AVD represents highly effective frontline therapy for CHL, but results in spurious PET findings in a significant proportion of patients despite most patients having undetectable ctDNA and no relapse. ctDNA may represent a more sensitive and specific response assessment tool to be studied in larger datasets.
Disclosures
Lynch:TG Therapeutics, Incyte, Bayer, Cyteir, Genentech, SeaGen, Rapt: Research Funding; Cancer Study Group: Consultancy. Alig:Takeda Pharmaceuticals: Consultancy. Ujjani:Abbvie: Consultancy, Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; Eli Lilly and Company: Consultancy, Research Funding; Loxo Oncology: Consultancy, Research Funding; Astara: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Genentech: Consultancy; Beigene: Consultancy; Incyte: Consultancy; Pharmacyclics: Consultancy, Research Funding; Adaptive Biotechnologies: Research Funding. Poh:Incyte Morphosys: Consultancy, Research Funding. Smith:Portola Pharmaceuticals: Research Funding; Abbvie: Consultancy; Numab Therapeutics AG: Consultancy; Nanjing Pharmaceuticals Co., Ltd.: Research Funding; MorphoSys: Research Funding; Merck Sharp and Dohme Corp.: Research Funding; Kymera Therapeutics: Research Funding; KITE pharma: Consultancy; Karyopharm: Consultancy; Incyte Corporation: Consultancy, Research Funding; Genentech: Research Funding; Enterome: Research Funding; Epizyme: Consultancy; Viracta Therapeutics: Research Funding; De Novo Biopharma: Research Funding; Beigene: Consultancy, Research Funding; Bayer: Research Funding; AstraZeneca: Consultancy, Research Funding; ADC Therapeutics: Consultancy, Research Funding. Shadman:Pharmacyclics: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Morphosys/Incyte: Consultancy, Research Funding; Kite Pharma: Consultancy; Adaptive Biotechnologies: Consultancy; Epizyme: Consultancy; Innate Pharma: Consultancy; Adaptimmune: Consultancy; Regeneron: Consultancy; Merck: Consultancy; Epi Lilly: Consultancy; Fate Therapeutics: Consultancy; Beigene: Consultancy, Research Funding; MEI Pharma: Consultancy; TG Therapeutics: Consultancy, Research Funding; Mustang Bio: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Sound Biologics: Consultancy; AstraZeneca: Consultancy, Research Funding; Atara Biotherapeutic: Consultancy, Research Funding; Celgene, a BMS Company: Research Funding; Gilead: Research Funding; Sunesis: Research Funding; Genmab: Research Funding. Shustov:Seagen: Current Employment, Current equity holder in publicly-traded company. Till:Mustang Bio: Consultancy, Patents & Royalties, Research Funding; BMS/Celgene: Research Funding; Proteios Technology: Consultancy. Alizadeh:Genentech: Consultancy; Roche: Consultancy; Gilead: Consultancy, Divested equity in a private or publicly-traded company in the past 24 months, Patents & Royalties; Syncopation: Current equity holder in private company, Patents & Royalties; Cibermed Inc: Consultancy, Current equity holder in private company, Patents & Royalties; Foresight Diagnostics: Consultancy, Current equity holder in private company, Patents & Royalties; BMS: Consultancy, Research Funding; Adaptive Biotechnologies: Consultancy; Karyopharm: Consultancy. Gopal:Incyte, Kite, Morphosys/Incyte, ADCT, Acrotech, Merck, Karyopharm, Servier, Beigene, Cellectar, Janssen, SeaGen, Epizyme, I-Mab bio, Gilead, Genentech, Lilly, Caribou, Fresenius-Kabi: Consultancy, Honoraria; Merck, I-Mab bio, IgM Bio, Takeda, Gilead, Astra-Zeneca, Agios, Janssen, BMS, SeaGen, Teva, Genmab: Research Funding.
